What is TissueGen?
Founded in 2000, TissueGen specializes in creating transformative drug delivery solutions designed to minimize the impact of treatments on patients and caregivers. The company's core expertise lies in its proprietary polymeric systems that maintain the biological integrity of sensitive therapeutics, enabling sustained release for both acute and chronic conditions. Leveraging advanced nanotechnology, TissueGen is at the forefront of developing long-term delivery mechanisms that promise to revolutionize pharmaceutical applications.
How much funding has TissueGen raised?
TissueGen has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for TissueGen?
With its recent major strategic investment and a history of substantial capital infusion, TissueGen is well-positioned for its next phase of growth. The company's focus on late-stage development suggests a trajectory towards broader market penetration and the scaling of its innovative drug delivery platforms. This strategic backing is expected to accelerate product development, expand clinical trials, and solidify TissueGen's market presence in the competitive biopharmaceutical landscape. The company's commitment to enhancing therapeutic efficacy and patient compliance will likely drive future innovation and investment.
See full TissueGen company page
